I'm thinking the cash burn rate could quite easily last far...

I'm thinking the cash burn rate could quite easily last far longer than 6 qtrs as the company commercialises its technology over the next year & becomes cash flow positive.

Payments for R&D could easily be at lower levels in the future and customer receipts will only increase from here (& this could happen quite rapidly).

The acquisition of Imbio will provide revenue & cost synergies for the company & SaaS revenue will also increase. Further, a reseller agreement is being put in place with Philips that could lead to rapid revenue increases for the company given the benefits of using its technology for toxic exposure and lung screening.

Further if there was any further need for another 'top up' it would likely make commercial sense, be at a share price far in excess of what we are seeing now & as a result no-one will be complaining.